Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.22.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 8,968 $ 5,297
Short-term investments 23,011
Prepaid expenses and other current assets 190 364
Total current assets 32,169 5,661
Current liabilities    
Accounts payable 8,189 2,243
Accrued expenses 1,901 1,296
Accrued interest 4,838
Convertible notes payable (net of discount of $4,519 at December 31, 2020) 26,303
Line of credit 31 31
Derivative liability 138 383
Total current liabilities 10,259 35,094
Stockholders’ equity (deficit)    
Common stock, par value $0.001, 750,000,000 shares authorized, 32,061,989 shares and 5,218,122 shares issued and outstanding as of December 31, 2021 and 2020, respectively 32 5
Common stock issuable 327,298 shares at December 31, 2021 1,113  
Additional paid in capital 674,348 566,356
Accumulated deficit (653,584) (595,797)
Total stockholders’ equity (deficit) 21,910 (29,433)
Total liabilities and stockholders’ equity (deficit) 32,169 5,661
Series C Preferred Stock [Member]    
Stockholders’ equity (deficit)    
Convertible Preferred stock 1 1
Series J Preferred Stock [Member]    
Stockholders’ equity (deficit)    
Convertible Preferred stock $ 2